Johnson & Johnson (NYSE:JNJ) Stake Lowered by Vigilare Wealth Management

Vigilare Wealth Management decreased its stake in Johnson & Johnson (NYSE:JNJ) by 23.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,908 shares of the company’s stock after selling 2,101 shares during the period. Vigilare Wealth Management’s holdings in Johnson & Johnson were worth $1,010,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Christopher J. Hasenberg Inc bought a new position in Johnson & Johnson in the 1st quarter worth approximately $31,000. Keener Financial Planning LLC purchased a new stake in Johnson & Johnson during the fourth quarter valued at about $40,000. WFA Asset Management Corp boosted its holdings in shares of Johnson & Johnson by 61.4% in the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after buying an additional 97 shares during the period. Vermillion & White Wealth Management Group LLC purchased a new position in shares of Johnson & Johnson in the fourth quarter worth approximately $44,000. Finally, Disciplined Equity Management Inc. purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $45,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on JNJ. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their target price for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. Bank of America dropped their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. StockNews.com lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a report on Tuesday, July 30th. Finally, Daiwa Capital Markets cut shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $173.21.

Johnson & Johnson Stock Down 0.5 %

Shares of Johnson & Johnson stock traded down $0.74 during midday trading on Monday, reaching $159.88. 7,603,456 shares of the company’s stock traded hands, compared to its average volume of 7,356,028. The company has a market cap of $384.78 billion, a price-to-earnings ratio of 9.94, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.60. The company’s 50 day simple moving average is $151.17 and its 200 day simple moving average is $153.06. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The company had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.80 earnings per share. Equities analysts expect that Johnson & Johnson will post 10.07 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.10%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.